Dihydromyricetin Attenuates Myocardial Hypertrophy Induced by Transverse Aortic Constriction via Oxidative Stress Inhibition and SIRT3 Pathway Enhancement

• Published in: International journal of molecular sciences Vol. 19; no. 9; p. 2592
• Main Authors: Chen, Yun, Luo, Hui-Qin, Sun, Lin-Lin, Xu, Meng-Ting, Yu, Jin, Liu, Lu-Lu, Zhang, Jing-Yao, Wang, Yu-Qin, Wang, Hong-Xia, Bao, Xiao-Feng, Meng, Guo-Liang
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 31.08.2018; MDPI
• Subjects: Animals; Antioxidants - pharmacology; Antioxidants - therapeutic use; Blood pressure; Cardiac function; Cardiomegaly - drug therapy; Cardiomegaly - etiology; Cardiomyocytes; Cell cycle; Flavonols - pharmacology; Flavonols - therapeutic use; Gene expression; Heart failure; Intubation; Kinases; Male; Mice; Mice, Inbred C57BL; Myocardium - metabolism; Oxidative stress; Oxidative Stress - drug effects; Phosphorylation; Reactive oxygen species; Signal Transduction - drug effects; Sirtuin 3 - metabolism; Substance abuse treatment; Variance analysis; Veins & arteries; Ventricular Outflow Obstruction - complications; China; myocardial hypertrophy; dihydromyricetin; sirtuin 3; oxidative stress

Dihydromyricetin (DMY), one of the flavonoids in vine tea, exerts several pharmacological actions. However, it is not clear whether DMY has a protective effect on pressure overload-induced myocardial hypertrophy. In the present study, male C57BL/6 mice aging 8–10 weeks were subjected to transverse a...